| Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, J Dennis, ... JNCI: Journal of the National Cancer Institute 109 (7), djw302, 2017 | 316 | 2017 |
| Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ... Journal of the National Cancer Institute 106 (6), dju089, 2014 | 219 | 2014 |
| Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target U Saini, S Naidu, AC ElNaggar, HK Bid, JJ Wallbillich, K Bixel, C Bolyard, ... Oncogene 36 (2), 168-181, 2017 | 116 | 2017 |
| Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma MA Krook, A Lenyo, M Wilberding, H Barker, M Dantuono, KM Bailey, ... Molecular cancer therapeutics 19 (3), 847-857, 2020 | 113 | 2020 |
| Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398 J Datta, S Damodaran, H Parks, C Ocrainiciuc, J Miya, L Yu, EP Gardner, ... Molecular cancer therapeutics 16 (4), 614-624, 2017 | 92 | 2017 |
| The role of PARP inhibitors in the treatment of gynecologic malignancies RE Reinbolt, JL Hays Frontiers in oncology 3, 237, 2013 | 87 | 2013 |
| A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer KDP Dorayappan, ML Gardner, CL Hisey, RA Zingarelli, BQ Smith, ... Cancer research 79 (13), 3503-3513, 2019 | 83 | 2019 |
| Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions DH Moon, JM Lee, AM Noonan, CM Annunziata, L Minasian, N Houston, ... British journal of cancer 109 (4), 1072-1078, 2013 | 75 | 2013 |
| Olaparib in the management of ovarian cancer K Bixel, JL Hays Pharmacogenomics and personalized medicine, 127-135, 2015 | 70 | 2015 |
| Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers KB Kuchenbaecker, SL Neuhausen, M Robson, D Barrowdale, ... Breast cancer research 16, 1-27, 2014 | 69 | 2014 |
| BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma ND Seligson, EA Kautto, EN Passen, C Stets, AE Toland, SZ Millis, ... The oncologist 24 (7), 973-979, 2019 | 53 | 2019 |
| Mixed adeno-neuroendocrine carcinoma: an aggressive clinical entity S Brathwaite, J Rock, MM Yearsley, T Bekaii-Saab, L Wei, WL Frankel, ... Annals of surgical oncology 23, 2281-2286, 2016 | 53 | 2016 |
| Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions MH Vetter, JL Hays Clinical therapeutics 40 (3), 361-371, 2018 | 47 | 2018 |
| Autophagy induction results in enhanced anoikis resistance in models of peritoneal disease JL Chen, J David, D Cook-Spaeth, S Casey, D Cohen, K Selvendiran, ... Molecular Cancer Research 15 (1), 26-34, 2017 | 43 | 2017 |
| A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety JL Hays, G Kim, A Walker, CM Annunziata, JM Lee, J Squires, N Houston, ... Molecular and clinical oncology 1 (3), 565-569, 2013 | 43 | 2013 |
| Appendiceal mixed adeno-neuroendocrine carcinoma: a population-based study of the surveillance, epidemiology, and end results registry S Brathwaite, MM Yearsley, T Bekaii-Saab, L Wei, CR Schmidt, ... Frontiers in oncology 6, 148, 2016 | 41 | 2016 |
| Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma KLJ Bill, ND Seligson, JL Hays, A Awasthi, B Demoret, CW Stets, ... The oncologist 24 (7), 989-996, 2019 | 32 | 2019 |
| Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer JM Lee, JL Hays, VL Chiou, CM Annunziata, EM Swisher, MI Harrell, ... Oncotarget 8 (45), 79175, 2017 | 32 | 2017 |
| Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi … EW Beal, LP Suarez-Kelly, CW Kimbrough, FM Johnston, J Greer, ... Journal of clinical medicine 9 (3), 748, 2020 | 31 | 2020 |
| The omics revolution continues: the maturation of high-throughput biological data sources E Mathé, JL Hays, DG Stover, JL Chen Yearbook of medical informatics 27 (01), 211-222, 2018 | 30 | 2018 |
